Trial Profile
A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Lapatinib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 28 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov
- 01 Jan 2014 Planned End Date changed from 1 Dec 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov